Indoco Remedies announced that it has received approval for its ANDA for Apixaban Tablets 2.5mg & 5mg.

The products are therapeutically equivalent to the Reference Listed Drug ‘Eliquis’ of Bristol-Myers Squibb (BMS).

Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot.

The US market size of Apixaban Tablets is $11,037 million as per IMS.

The stock price has reacted positively to this news and it rose 9.5% to Rs.242.05. Its 20% UC for the day is at Rs.265.40 and 52-week high at Rs.285.